S-SPIRE Center, Department of Surgery, Stanford University, Stanford, California.
Stanford University, Department of Health Research and Policy, Stanford, California.
Dis Colon Rectum. 2019 May;62(5):586-594. doi: 10.1097/DCR.0000000000001342.
Sex-based treatment disparities occur in many diseases. Women undergo fewer procedural interventions, and their care is less consistent with guideline-based therapy. There is limited research exploring sex-based differences in ulcerative colitis treatment. We hypothesized that women are less likely to be treated with strategies consistent with long-term disease remission, including surgery and maintenance medications.
The aim of this study was to determine if patient sex is associated with choice of treatment strategy for ulcerative colitis.
This is a retrospective cohort analysis.
Data were gathered from a large commercial insurance claims database from 2007 to 2015.
We identified a cohort of 38,851 patients newly diagnosed with ulcerative colitis, aged 12 to 64 years with at least 1 year of follow-up.
The primary outcomes measured were the differences between male and female patients in 1) rates and types of index ulcerative colitis operations, 2) rates and types of ulcerative colitis medication prescriptions, and 3) rates of opioid prescriptions.
Men were more likely to undergo surgical treatment for ulcerative colitis (2.94% vs 1.97%, p < 0.001, OR 1.51, p < 0.001). The type of index operation performed did not vary by sex. Men were more likely to undergo treatment with maintenance medications, including biologic (12.4% vs 10.2%, p < 0.001, OR 1.22, p < 0.001), immunomodulatory (16.3% vs 14.9%, p < 0.001, OR 1.08, p = 0.006), and 5-aminosalicylate medications (67.0% vs 63.2%, p < 0.001, OR 1.18, p < 0.001). Women were more likely to undergo treatment with rescue therapies and symptomatic control with corticosteroids (55.5% vs 54.0%, p = 0.002, OR 1.07, p = 0.002) and opioids (50.2% vs 45.9%, p < 0.001, OR 1.17, p < 0.001).
Claims data lack clinical characteristics acting as confounders.
Men with ulcerative colitis were more likely to undergo treatment consistent with long-term remission or cure, including maintenance medications and definitive surgery. Women were more likely to undergo treatment consistent with short-term symptom management. Further studies to explore underlying mechanisms of sex-related differences in ulcerative colitis treatment strategies and disease trajectories are warranted. See Video Abstract at http://links.lww.com/DCR/A943.
许多疾病中存在基于性别的治疗差异。女性接受的程序干预较少,其治疗与基于指南的治疗方案不太一致。目前关于溃疡性结肠炎治疗中基于性别的差异的研究有限。我们假设女性接受符合长期疾病缓解策略(包括手术和维持性药物治疗)的可能性较低。
本研究旨在确定患者性别是否与溃疡性结肠炎的治疗策略选择相关。
这是一项回顾性队列分析。
数据来自 2007 年至 2015 年的大型商业保险索赔数据库。
我们确定了一个新诊断为溃疡性结肠炎的队列,年龄为 12 至 64 岁,至少有 1 年的随访。
主要结局指标是男性和女性患者在 1)溃疡性结肠炎指数手术的发生率和类型、2)溃疡性结肠炎药物处方的发生率和类型、3)阿片类药物处方的发生率方面的差异。
男性更有可能接受溃疡性结肠炎的手术治疗(2.94% vs 1.97%,p<0.001,OR 1.51,p<0.001)。手术类型不受性别影响。男性更有可能接受维持性药物治疗,包括生物制剂(12.4% vs 10.2%,p<0.001,OR 1.22,p<0.001)、免疫调节剂(16.3% vs 14.9%,p<0.001,OR 1.08,p=0.006)和 5-氨基水杨酸类药物(67.0% vs 63.2%,p<0.001,OR 1.18,p<0.001)。女性更有可能接受救治疗法和皮质类固醇(55.5% vs 54.0%,p=0.002,OR 1.07,p=0.002)和阿片类药物(50.2% vs 45.9%,p<0.001,OR 1.17,p<0.001)进行症状控制治疗。
索赔数据缺乏作为混杂因素的临床特征。
患有溃疡性结肠炎的男性更有可能接受符合长期缓解或治愈的治疗,包括维持性药物治疗和确定性手术治疗。女性更有可能接受符合短期症状管理的治疗。需要进一步的研究来探索溃疡性结肠炎治疗策略和疾病轨迹中与性别相关的差异的潜在机制。详见视频摘要,网址:http://links.lww.com/DCR/A943。